skin. 20, 26, 35 Growing tumors may involve the CA at the neck or the skull base, thereby increasing the challenge of treatment. The decision to intervene in cases of CA involvement depends on tumor type, tumor location, and systemic disease status. 40 Treatment options for advanced head and neck cancers involving the CA include hospice care, nonsurgical adjuvant therapy, CA peeling, and CA resection with or without revascularization. 6, 16, 17, 24 The risks of stroke and death involved with sacrificing the CA are significant. 22, 23, 37 To decrease the overall morbidity and mortality rates associated with CA sacrifice, revascularization may be performed. Related complications, such as bypass rupture and occlusion, 12, 23, 41 and the inability of existing tests to predict cerebral vascular reserve, 10, 25, 29 pose further challenges to this strategy. When cancers involve the CA in the neck, carotid sacrifice improves the 2-year survival rate but is associated with a significant risk of neurological deficits, stroke, and delayed ischemic complications. 1, 3, 5, 21, 28, 41 The perioperative mortality rate ranges from 0% to 45%, and the rate of de novo aneurysm formation ranges from 1% to 10%. 1, 3, 5, 21, 28, 41 Involvement of the ICA at the skull base (cavernous sinus, petrous, or infratemporal segments) has been considered a contraindication for resection. 36 However, some surgeons have argued that there may still be a role for such an approach. 6, 16, 28 To evaluate this possibility we analyzed our approach, which consisted of bypass and resection for treatment of CA involvement with tumors at the skull base.
Methods
We retrospectively reviewed the charts of all patients with recurrent or progressive advanced head and neck cancers involving the ICA at the skull base who underwent ICA sacrifice with revascularization in which an extracranial-intracranial bypass was used between 1995 and 2010 at the Barrow Neurological Institute. Followup was based on telephone calls to patients, families, and primary care physicians, as well as on our office records. Patient hospital and office records were evaluated retrospectively.
Altogether, 18 patients (11 male and 7 female patients; mean age 46 years, range 7-69 years [ Table 1 ]) with recurrent or progressive malignancies involving the ICA at the level of infratemporal fossa, petrous bone, or cavernous sinus were treated (Fig. 1) . Nine of these patients have been reported in other studies from our group. However, only 5 of these 9 patients were analyzed for survival outcomes; the other 4 were described as a part of a technical report. 9, 11, 39 The MRI studies showed that the infratemporal ICA was involved by tumor in 9 patients, the petrous ICA in 3 patients, and the cavernous ICA in 6 patients. All patients underwent preoperative angiography, but their cerebrovascular reserve was not evaluated because vascular reconstruction was planned in all cases. All patients underwent an extracranial-intracranial bypass, which included a direct ipsilateral bypass with a SVG [32] [33] [34] Table 2 summarizes the outcomes of the patients. Immediately after surgery (within the first 24 hours) the bypass was functional and patent in all 18 patients (immediate patency rate 100%), but 1 bypass failed (overall patency rate 94.4%) in the postoperative period. Three complications (16.7%) were associated with the bypass surgery: 1 SDH associated with blindness (Case 1), 1 stroke (Case 12), and 1 asymptomatic bypass occlusion (Case 18). The patient with the stroke (Case 12) died within the postoperative period. At surgery another patient (Case 15) was found to have radiation effect instead of tumor; consequently, this patient unnecessarily underwent ICA sacrifice and bypass.
Results
The tumors were resected in the remaining 16 patients (88.9%). Six complications (33.3%) were associated with the resection of tumors: 3 cases of CSF leakage (16.7%-Cases 2, 11, and 14); 1 case each of hydrocephalus (Case 8) and iatrogenic vascular injury to the contralateral ICA (Case 17); and the patient who was found to have radiation effect at surgery (Case 15) suffered an SDH related to anticoagulation therapy and had status epilepticus.
Two patients died (surgery-related mortality rate 11.1%). Besides the patient who had a stroke from occlusion of the bypass, a second patient (Case 6) died of infection and pneumocephalus related to a fistula between his oral and cranial cavities.
Histological evaluation of the ICA for tumor invasion was available in 7 cases. In a single case, histological examination of the specimen confirmed invasion of the ICA wall by tumor (Fig. 4) . Histologically, except in the case of treatment effect, all resected specimens were confirmed to be malignancies.
The interval between revascularization and tumor resection ranged from 1 to 37 days (mean 9.1 days, median 7 days). The length of hospitalization ranged from 13 to 43 days (mean 22, median 20 days). Eight patients (44.4%) were discharged to home, 2 (11.1%) to rehabilitation, and 3 (16.7%) to a skilled nursing facility. Data were unavailable for 3 patients (16.7%).
All patients died of progression of their disease, but no information was available on local versus distant recurrence of disease in most cases. The overall mean and median follow-up (excluding the surgery-related deaths) was 13.2 and 8.3 months, respectively (range 1.5-48 months). Including the surgery-related deaths, the mean and median follow-up of patients was 11.8 and 8 months, respectively (range 17 days-48 months).
Five patients survived longer than 12 months (overall 1-year survival rate 27.8%). Of these patients, 1 had a palatal SCC, 1 had a rhabdomyosarcoma (in which the final pathological finding was consistent with treatment effect), and 3 had an adenocystic carcinoma. Only 2 patients survived longer than 24 months (overall 2-year survival rate 11.1%). One of them had a palatal SCC, and the second had an adenocystic carcinoma. Based on subgroup analysis, patients with adenocystic cancers survived an average of 28.7 months (range 18-48, median 20 months), whereas those with nonadenocystic cancers (excluding the patient with the treatment effect and no viable cancer) survived an average of 7.4 months (range 17 days-23 months, median 5.5 months).
Discussion
Three collaborative international studies have established the morbidity, mortality, and median survival rates for patients with skull base malignancies following craniofacial resections. [13] [14] [15] Surgical complications were noted in one-quarter to one-third of patients with skull base malignancies (range 25%-36.3%), and their rate of postoperative mortality ranged from 1.4% to 4.8%. These studies reported 5-year overall and recurrence-free survival rates of 61%-62% and of 55%-57%, respectively.
13-15
In separate studies of patients undergoing infratemporal resections of skull base malignancies, complications occurred in 28%-31% of cases, with a 4% mortality rate.
4,20
Our morbidity and mortality rates were 33.3% and 11.1%, respectively. The median survival rate in our series was 8 months. Although our morbidity rate is within the published range, our mortality and survival rates are worse than those reported by others. [13] [14] [15] Sacrifice of the CA in the neck has been associated with better results than sacrifice of that vessel in the skull base. 3, 5, 21, 28 Malignancies that extensively involve the skull base or that extend into the cavernous sinus, pituitary gland, or orbit are usually contraindications for surgical intervention. 36 Several studies have challenged this view and suggested that there may be an indication to pursue aggressive tumor resection and CA sacrifice with concomitant revascularization. 6 in good condition, 1 died 2.5 years after surgery without evidence of local recurrence, and 2 experienced vascular occlusion of their bypass with 1 major stroke. Nayak et al. 28 described 6 patients who underwent revascularization and carotid sacrifice at the skull base. None of these patients survived beyond 2 years, but 2 survived 9 and 12 months after surgery, respectively, and a third survived 14 months before dying.
The argument that CA sacrifice and bypass may improve survival for patients with malignancies at the skull base may be specific to the histological type of the cancer. In our series the 1-and 2-year survival rates were 27.8% and 11.1%, respectively. Of the 5 patients who survived beyond 1 year, 3 had adenocystic carcinomas, 1 had a rhabdomyosarcoma (which intraoperatively was noted to be scar tissue and not tumor), and 1 had an SCC. A prior study had highlighted the improved outcome of patients with adenocystic cancers after carotid resection and revascularization. 16 We also noted that patients with this type of tumor survived longer after aggressive resection and bypass compared with patients with nonadenocystic tumors.
The actual ability of tumor to invade the CA has been debated. In some case reports of microscopically evaluated cancer-invaded cavernous sinus, no invasion of the ICA by the tumor was found-only encasement of the artery.
7,27 One of our patients had pathologically proven invasion of the vessel by tumor. Although physical vascular invasion may be rare, extensive encasement without malignant invasion of the vessel wall would still require sacrifice of the ICA to attempt to achieve microscopically negative margins. Due to the paucity of data, we could not demonstrate that resection of the ICA at the skull base for malignancies allowed us to achieve a microscopically negative margin.
With high rates of morbidity and mortality, poor postresection survival rates, and improved survival with chemoradiotherapy, 30 ,31 the role of aggressive resection has been questioned. 19 In some series of skull base tumors treated with adjuvant therapies, overall survival rates at 2 and 3 years have been reported at 80% and 36%, respectively. 18, 19 Our data indicate that despite resection, the presence of ICA involvement in advanced head and neck cancers portends a worse prognosis, with higher morbidity and mortality rates, compared with patients without ICA involvement. Given this trend toward poor outcomes, the futility of this procedure outweighs its benefits in most cases. It should be used with caution and only after careful patient selection.
Conclusions
The ideal treatment regimen for malignant tumors involving the CA at the skull base remains nonsurgical. On certain occasions, carotid sacrifice and bypass may have a role in the treatment of tumors with less aggressive biological behaviors, such as adenocystic carcinomas. Given the high rates of surgery-related mortality and poor survival despite aggressive measures, we interpret our results and those of other authors as indicating that in cases of aggressive malignancies, CA involvement at the skull base is a relative contraindication to revascularization and aggressive resection. 
